Seeking Alpha

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM ...

—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the ...
The Trentonian

ARIKAYCE(R) (amikacin liposome inhalation suspension) Approved by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by ...

BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Nasdaq

Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Seeking Alpha

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG ...

—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— ...
Monthly Prescribing Reference

Survey: Management of Amikacin Liposome Inhalation Suspension-Associated Respiratory Adverse Events

Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea. Results from a ...
FiercePharma

Insmed Announces Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq:INSM) today announced additional results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for ...
CNN

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Business Insider

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory ...

Study met primary endpoint of culture conversion (p< 0.0001) Positive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection ...
FiercePharma

Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia

Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia WAYNE, N.J., April 16, 2013 /PRNewswire/ -- ...
Business Insider

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...
WOOD-TV

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG ...

BRIDGEWATER, N.J., Sept. 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...